GABARNANCE TRIAL

Randomized phase II/III study of gemcitabine and nab-paclitaxel therapy versus S-1 and concurrent radiotherapy as neoadjuvant treatment for Borderline resectable pancreatic cancer

About us・Member Institutions

Randomized phase II/III study of gemcitabine and nab-paclitaxel therapy versus S-1 and concurrent radiotherapy as neoadjuvant treatment for Borderline resectable pancreatic cancer - GABARNANCE Trial

Study Group

  • The study group by Research and development budget from Japan Agency for Medical Research and Development (Practical Research for Innovative Cancer Control)
  • Japan Adjuvant Study Group for Pancreatic Cancer(JASPAC)

Participating Institutions (23 institutions)

Institution Department Institutional Investigator Institutional Coordinator
Aichi Cancer Center Hospital Gastrointestinal Surgery Yasuhiro Shimizu Nobuyoshi Mizuno
Asahikawa Medical University Surgery II Hiroyuki Furukawa Keisuke Yamakita
Kagawa University Hospital Gastrointestinal Surgery Yasuyuki Suzuki Hiroyuki Okuyama
Kanagawa Cancer Center Gastrointestinal Surgery, Liver, Gallbladder, Pancreas Soichiro Morinaga Makoto Ueno
Kyushu Cancer Center Hepatobiliary and Pancreatic Surgery Keishi Sugimachi Keishi Sugimachi
Gunma Prefectural Cancer Center Gastrointestinal Surgery Hitoshi Ojima Yasushi Mochida
Kobe University Hospital Hepatobiliary and Pancreatic Surgery Takumi Fukuyama Hirochika Toyama
National Cancer Center Hospital East Hepatobiliary and Pancreatic Surgery Shinichiro Takahashi Yusuke Hashimoto
National Hospital Organization Osaka National Hospital Hepatobiliary and Pancreatic Surgery Atsushi Miyamoto Atushi Miyamoto
Saitama Cancer Center Gastrointestinal Surgery Amane Takahashi Amane Takahashi
Sapporo Medical University Hospital Gastrointestinal Surgery Yasutoshi Kimura Masayo Motoya
Shikoku Cancer Center Gastrointestinal Surgery Koji Ota Koji Ota
Shizuoka Cancer Center Hepatobiliary and Pancreatic Surgery Katsuhiko Uesaka Teiichi Sugiura
Jichi Medical University Hospital Gastrointestinal Surgery Hiroki Ymaguchi Yasunari Sakuma
St.Marianna University School of Medicine Hospital Gastrointestinal Surgery Takehito Otsubo Yoshiki Horie
Chiba Cancer Center Gastrointestinal Surgery Wataru Takayama Hiroo Yanagihashi
Teine Keijinkai Hospital Gastroenterology Akio Katanuma Takeshi Hyashi
Tokyo Women’s Medical University Hospital Gastrointestinal Surgery Masakazu Yamamoto Ryota Higuchi
Tohoku University Hospital Department of Surgery Michiaki Unno Tatsuyuki Takadate
Tochigi Cancer Center Surgery Moriaki Tomikawa Moriaki Tomikawa
Fukuyama City Hospital Surgery Hiroshi Sadamori Katsuyoshi Hioki
Hokkaido University Hospital Gastrointestinal Surgery II Satoshi Hirano Toru Nakamura
Yamagata University Surgery I Fuyuhiko Motoi Ryosuke Takahashi

Study Organization

  • Group leader of AMED-funded research: Shinichiro Takahashi
    Medical Device Project Management Office / Hepato-Biliary Pancreatic Surgery Division, National Cancer Center Hospital East
  • Principal Investigator: Masafumi Ikeda
    Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East
  • Study Secretariat: Yusuke Hashimoto
    Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East
  • JASPAC Group Leader: Katsuhiko Uesaka
    Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center
  • Central Imaging Assessment Manager: Tatsuji Kobayashi
    Department of Diagnostic Radiography, National Cancer Center Hospital East
  • Radiotherapy Study Secretariat: Tetsuo Akimoto
    Department of Diagnostic Radiography, National Cancer Center Hospital East
  • Statistical Analysis Manager: Shogo Nomura
    Department of Biostatistics, Graduate School of Medicine, The University of Tokyo, Department of Biometrics and Intelligence
  • Data Center: Akira Ikeda
    Data Center Division 2 Office 2, Clinical Research Headquarters, J-CRSU

Funding Source

Research and development budget from Japan Agency for Medical Research and Development (Practical Research for Innovative Cancer Control)

Group Leader: Shinichiro Takahashi (Medical Device Project Management Office / Hepato-Biliary Pancreatic Surgery Division, National Cancer Center Hospital East)